Expanding the Role of Immunotherapy: New Regimens for Use in the Adjuvant and Neoadjuvant Settings

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 75 Minutes

Overview

Immunotherapy has revolutionized cancer treatment. During this session, expert faculty will review important data related to the use of immunotherapy in the neoadjuvant and adjuvant settings. Participants will dive into a comparison of conventional chemotherapy and adjuvant and neoadjuvant immunotherapy, as well as recent FDA approvals in the neoadjuvant setting. 

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Review the critical preclinical data and clinical pharmacology considerations that differentiate immunotherapies within the neoadjuvant and adjuvant treatment settings 

2. Compare and contrast the application of conventional chemotherapy with that of immunotherapy in the neoadjuvant and adjuvant treatment settings

3. Identify the advantages and disadvantages of conventional chemotherapy and immunotherapy when used in the neoadjuvant and adjuvant settings

4. Discuss immunotherapeutics recently FDA-approved in the neoadjuvant setting                                                                                                           

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
Course opens: 
04/19/2024
Course expires: 
04/19/2025
Cost:
$0.00
Rating: 
0

Faculty

Anthony J. Olszanski, RPh, MD 

Dr. Olszanski, Vice-Chair of the Department of Hematology/Oncology at Fox Chase Cancer Center, is the director of the Early Clinical Drug Development Phase I Program and co-director of the Melanoma and Skin Cancer Program. Dr. Olszanski completed his hematology and oncology fellowship and clinical pharmacology fellowship at Dartmouth-Hitchcock Medical Center. He is board-certified in internal medicine, medical oncology, and clinical pharmacology. He focuses on the treatment of lung cancer and cutaneous malignancies with a focus on melanoma. He sits on the NCCN Melanoma guidelines panel and the Management of Immunotherapy-Related Toxicities. Dr. Olszanski serves as a mentor to numerous oncology fellows, internal medicine residents and colleagues. In addition to attracting a large number of sponsored Phase I trials, he has written, developed, and run (or served as a sub-investigator on) many investigator-initiated trials. Dr. Olszanski has served as the principal investigator on more than 50 trials.. 

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Anthony J. Olszanski, RPh, MD discloses advisory board with BMS, Merck, Pfizer, Novartis, Eisai, Nectar, InstillBio but these relationships have ended and contracted research with Alkermes, antegene, Elucida, Eutilex, GSK, HiFiBio, Immatics during the past 24 months.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.

Price

Cost:
$0.00
Please login or register to take this course.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test
  4. Submit the evaluation form

DISCLAIMER:

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above